202 related articles for article (PubMed ID: 33388283)
1. Nanobodies as probes to investigate purinergic signaling.
Eggers M; Rühl F; Haag F; Koch-Nolte F
Biochem Pharmacol; 2021 May; 187():114394. PubMed ID: 33388283
[TBL] [Abstract][Full Text] [Related]
2. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
3. Purinergic signaling in diabetes and metabolism.
Jain S; Jacobson KA
Biochem Pharmacol; 2021 May; 187():114393. PubMed ID: 33359363
[TBL] [Abstract][Full Text] [Related]
4. History of ectonucleotidases and their role in purinergic signaling.
Zimmermann H
Biochem Pharmacol; 2021 May; 187():114322. PubMed ID: 33161020
[TBL] [Abstract][Full Text] [Related]
5. Development of Antibody and Nanobody Tools for P2X7.
Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
[TBL] [Abstract][Full Text] [Related]
6. Purinergic signalling in host innate immune defence against intracellular pathogens.
Coutinho-Silva R; Savio LEB
Biochem Pharmacol; 2021 May; 187():114405. PubMed ID: 33406411
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Retinal Disorders with Purinergic Drugs: Beyond Receptors.
Beckel JM; Lu W; Civan MM; Mitchell CH
J Ocul Pharmacol Ther; 2016 Oct; 32(8):488-489. PubMed ID: 27754823
[No Abstract] [Full Text] [Related]
8. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
9. Purinergic signalling in the kidney: In physiology and disease.
Monaghan MT; Bailey MA; Unwin RJ
Biochem Pharmacol; 2021 May; 187():114389. PubMed ID: 33359067
[TBL] [Abstract][Full Text] [Related]
10. Applications of nanobodies in plant science and biotechnology.
Wang W; Yuan J; Jiang C
Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
[TBL] [Abstract][Full Text] [Related]
11. Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.
Menzel S; Schwarz N; Haag F; Koch-Nolte F
Front Pharmacol; 2018; 9():266. PubMed ID: 29636685
[TBL] [Abstract][Full Text] [Related]
12. Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.
Liu B; Yang D
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163405
[TBL] [Abstract][Full Text] [Related]
13. A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7
Gondé H; Demeules M; Hardet R; Scarpitta A; Junge M; Pinto-Espinoza C; Varin R; Koch-Nolte F; Boyer O; Adriouch S
Front Immunol; 2021; 12():704408. PubMed ID: 34489954
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.
Ji F; Ren J; Vincke C; Jia L; Muyldermans S
Methods Mol Biol; 2022; 2446():3-17. PubMed ID: 35157266
[TBL] [Abstract][Full Text] [Related]
15. Introduction to the Special Issue on Purinergic Receptors.
Burnstock G
Adv Exp Med Biol; 2017; 1051():1-6. PubMed ID: 28224484
[TBL] [Abstract][Full Text] [Related]
16. Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.
Baum N; Eggers M; Koenigsdorf J; Menzel S; Hambach J; Staehler T; Fliegert R; Kulow F; Adam G; Haag F; Bannas P; Koch-Nolte F
Front Immunol; 2021; 12():703574. PubMed ID: 34539634
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies: natural single-domain antibodies.
Muyldermans S
Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
[TBL] [Abstract][Full Text] [Related]
19. Exploiting Nanobodies' Singular Traits.
Ingram JR; Schmidt FI; Ploegh HL
Annu Rev Immunol; 2018 Apr; 36():695-715. PubMed ID: 29490163
[TBL] [Abstract][Full Text] [Related]
20. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
